Wave Life Sciences Ltd. | Johnson Fistel

WAVE LIFE SCIENCES Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

SAN DIEGO – Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Wave Life Sciences Ltd. (NASDAQ: WVE). The investigation focuses on Wave Life Sciences’ executive officers and whether investor losses may be recovered under federal securities laws.

What if I purchased Wave Life Sciences securities?

Company

This field is for validation purposes and should be left unchanged.

If you suffered a loss on your investment and would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. The information provided will be held in strict confidence unless and until you authorize us to disclose it.

Name(Required)

First Last

Email(Required)

Phone(Required)

Estimated Losses(Required)

Where did you see our press release?(Required)

If you selected 'Other' above, please specify below:(Required)

Would you like to receive future case and securities updates from Johnson Fistel, PLLP via email?(Required)

Yes

Would you like to receive information about Johnson Fistel, PLLP's free portfolio monitoring service?(Required)

Yes

By checking the box, I acknowledge that this form is not intended to and does not establish an attorney-client relationship between myself and Johnson Fistel, PLLP, and that submission to or receipt of information from the firm or one of its attorneys via this form, website, email, or telephone does not create an attorney-client relationship.(Required)

I Agree

Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471.
There is no cost or obligation to you.

Background of the investigation
On March 26, 2026, Wave Life Sciences announced interim Phase 1 INLIGHT clinical data for WVE-007. The Company reported that a single 240 mg dose resulted in a placebo-adjusted reduction in visceral fat of approximately 14% at six months, along with reductions in total fat and waist circumference and preservation of lean mass. The Company also reported modest reductions in body weight and noted that the trial population had a lower baseline body mass index than patients typically enrolled in later-stage obesity studies.

Following these disclosures, Wave Life Sciences’ stock price declined significantly on March 26, 2026.

In light of this disclosure, Johnson Fistel is investigating whether Wave Life Sciences complied with the federal securities laws. If you suffered losses from your investment in Wave Life Sciences stock, contact Johnson Fistel.

About Johnson Fistel, PLLP | Securities Fraud & Investor Rights
Johnson Fistel, PLLP is a nationally recognized shareholder-rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits and also assists foreign investors who purchased shares on U.S. exchanges. To learn more, visit www.johnsonfistel.com.

Achievements
In 2024, Johnson Fistel was ranked among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services, reflecting the firm’s effectiveness in advocating for investors and recovering approximately $90,725,000 for clients in cases where it served as lead or co-lead counsel.

Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.

Contact
Johnson Fistel, PLLP
501 W. Broadway, Suite 800
San Diego, CA 92101
James Baker, Investor Relations – or – Frank J. Johnson, Esq.
(619) 814-4471 | jimb@johnsonfistel.com | fjohnson@johnsonfistel.com